Furthermore, macrophage activation and subtype switching, a key event at middle-stage of cardiac hypertrophy, was effectively attenuated by Dapagliflozin, a sodium glucose cotransporter 2 inhibitor known for its beneficial effects in heart failure patients, as well as two additional anti-inflammatory agents, inhibitor of galectin-3 (TD139) and Arglabin, which are rarely used in setting of cardiac diseases. Here, LGALS3 is linked to cardiac hypertrophy.